DexCom (DXCM) Tops Q2 EPS by 9c ; Offers Guidance
Tweet
Share
E-mailGet Alerts DXCM Hot Sheet
Price: $84.51 +0.75%
Revenue Growth %: +9.9%
Financial Fact:
Interest income: 100K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +9.9%
Financial Fact:
Interest income: 100K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
DexCom (NASDAQ: DXCM) reported Q2 EPS of $0.70, $0.09 better than the analyst estimate of $0.61. Revenue for the quarter came in at $1.31 billion versus the consensus estimate of $1.29 billion.
GUIDANCE:
DexCom sees FY2026 revenue of $5.18-5.25 billion, versus the consensus of $5.22 billion.
For earnings history and earnings-related data on DexCom (DXCM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Vistra prices $1.5B junior subordinated notes offering due 2057
- Wedbush Assumes Tenable (TENB) at Underperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
